Ad hoc announcement pursuant to Art. 53 LR MILAN, Italy and MORRISTOWN, N. J., Sept. 22, 2026 (GLOBE NEWSWIRE) — Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the first half of 2026, and provided a corporate update. Highlights H1 2026: EvenamideENIGMA-TRS 1: Screening for enrollment completed post-period in September. Target enrollment of at least 600 patients expected around mid-October, Topline 12-week results in Q1 2027 ENIGMA-TRS 2: Following a constructive Type A meeting with the FDA in July, Newron expects US enrollment to resume in the near future. Ongoing enrollment outside the US IP: European...

MEMPHIS, Tenn., Sept. 22, 2026 (GLOBE NEWSWIRE) — AutoZone, Inc. (NYSE: AZO) today reported net sales of $6.6 billion for its fourth quarter (16 weeks) ended August 29, 2026, an increase of 5.6% from the fourth quarter of fiscal 2025 (16 weeks). Same store sales, or sales for our domestic and international stores open at least one year, are as follows:                     Constant Currency       Constant Currency  16 Weeks   16 Weeks*   52 Weeks   52 Weeks*               Domestic 1.6 %   1.6 %   3.3 %   3.3 %International 10.7 %   1.3 %   13.5 %   2.2 %Total Company 2.7 %   1.5 %   4.5 %   3.2 %* Excludes impacts from fluctuations of foreign exchange rates.          For the quarter, gross profit, as a percentage of sales, was 53.3%, an increase of 182 basis points versus the prior year. The increase in...

BEIJING, Sept. 22, 2026 (GLOBE NEWSWIRE) — Here Group Limited (NASDAQ: HERE) (“Here” or the “Company”), an IP1-based pop toy company dedicated to creating beloved collectibles and trend-defining experiences, today announced its unaudited financial results for the fourth quarter and full year of the fiscal year ended June 30, 2026 (the “fourth quarter of FY 2026”, which refers to the quarter from April 1, 2026 to June 30, 2026, and “FY 2026”, which refers to the year from July 1, 2025 to June 30, 2026). Highlights for the Fourth Quarter of FY 20262Revenues for the fourth quarter of FY 2026 were RMB127.7 million (US$18.8 million), representing a decrease of 22.5% from the third quarter of the fiscal year ended June 30, 2026 (the “third quarter of FY 2026”), and representing an increase of 94.1% from the fourth quarter of the fiscal...

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon publication of this announcement, this inside information is now considered to be in the public domain. DXS INTERNATIONAL PLC (AQSE: DXSP) ANNUAL RESULTS for the year ended 30 April 2026 The Board of DXS International plc (AQSE: DXSP)(“the Company”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce its audited Final Results for the year ended 30 April 2026. Financial HighlightsProfit of £61,839 (2025: loss of £94,750). Revenue decreased...

ABC arbitrage HY 2026 Consolidated Results¹: €26.0 m (+47%) Annualised ROE 2026: 27.4% | EPS HY 2026: €0.44The Board of Directors of ABC arbitrage, presided by the Chairman Dominique Ceolin, met on September 17, 2026 to approve the consolidated financial statements for the first semester 2026¹. Key financial data are as follows:In millions of euros June 30, 2026 IFRS June 30, 2025 IFRS Var % Dec. 31, 2025 IFRSCurrent operating income €51.0 m €36.5 m 40% €59.7 mNet income €26.0 m €17.7 m 47% €25.1 mEarnings per share (EPS) €0.44 €0.30 47% €0.42Return on equity (ROE) 27.4 % 20.3 % 35% 14.8 %Equity €189.2 m €174.4 m 8% €169.6 mContext – In the first half of 2026, the progressive increase in volatility culminated in a significant period of stress, without, however, reaching the levels recorded in April 2025. Over the...

Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growth Positive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA action date of February 2027 with eligibility for expedited review through the National Priority Voucher program, which could result in an earlier FDA decision Litigation with GSK and Tesaro: trial held in July; post-trial hearing scheduled for October 20, 2026, with a judgement anticipated in Q4 2026 or Q1 2027SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported...

Gross margin expands to 68%; G&A down 25%; Company advances capital restructuring SÃO PAULO, Sept. 21, 2026 (GLOBE NEWSWIRE) — NVNI Group Limited (NASDAQ: NVNI) (“Nuvini” or the “Company”), an acquirer and operator of B2B SaaS companies in Brazil and Latin America, today reported unaudited results for the six months ended June 30, 2026, as filed with the U.S. Securities and Exchange Commission on Form 6-K. FIRST HALF 2026 HIGHLIGHTS Compared with the six months ended June 30, 2025; amounts in Brazilian reais.Net operating revenue of R$97.4 million, essentially flat; platform subscription revenue of R$90.5 million, 93% of total revenue Gross profit of R$66.3 million, up 7.0%; gross margin expanded 500 basis points to 68.1% in first half 2026 General and administrative expenses reduced 24.6% to R$31.6 million; total personnel...

Revenues rose 36.6% year over year, mainly driven by higher average selling prices AI infrastructure and liquid cooling continue to gain strategic importance, with large-volume customer orders secured subsequent to the first half of 2026SHENZHEN, China, Sept. 21, 2026 (GLOBE NEWSWIRE) — ZJK Industrial Co., Ltd. (NASDAQ: ZJK) (“ZJK” or the “Company”), a high-tech precision parts and hardware manufacturer serving artificial intelligence (AI) infrastructure, consumer electronics, electric vehicles, aerospace, and other smart technologies, today announced its unaudited financial results for the six months ended June 30, 2026. First Half of Fiscal Year 2026 Financial HighlightsRevenues were US$33.74 million for the first half of 2026, an increase of 36.60% from US$24.70 million for the same period of 2025. Gross profit was US$14.29 million...

~ Adding a Second Metal Endowment at the Steller Project~ VANCOUVER, British Columbia, Sept. 21, 2026 (GLOBE NEWSWIRE) — Blue Jay Gold Corp. (TSXV: JAY) (OTCQB: JAYGF) (FSE: JAY) (“Blue Jay” or the “Company”), today reported results from the metallurgical test program on mineralization from the Becker-Cochran antimony occurrence at its Steller Gold Project (“Steller” or the “Project”) in southern Yukon. Our maiden test work at ALS Metallurgical Laboratories in Kamloops, British Columbia delivered a flowsheet design producing a 67% antimony (“Sb”) concentrate at a 94% recovery. Roughly 50 kg of the concentrate is now being converted into finished antimony products by three North American processing groups who are looking to secure access to long-term supply, with first products expected in the coming weeks. Our test does not end...

Press release Societe Generale presents an ambitious strategic roadmap supportedby disciplined execution Paris, 21 September 2026 A new phase of disciplined, profitable and value-creating growthSociete Generale presents its strategic roadmap for 2029, opening a new development phase after the successful transformation initiated in 2023. With a simplified model, an improved risk profile, increased discipline in capital allocation, and a substantially improved financial performance, the Group is now entering a new stage of value creation based on four main priorities:Decrease further our cost base: the Group will pursue its cost reduction efforts, continuing the structural measures successfully undertaken in recent years, by relying on traditional levers of simplification, operational efficiency and technological transformation, as well...